908 Devices

908 Devices, Inc. engages in the development of measurement devices for chemical and biochemical analysis. It offers products using mass spectrometry technology, an analytical technique for measuring the mass of charged molecules that is used in chemical analysis laboratories for applications, such as safety and security, food science, biotechnology, clinical diagnostics, and controlling industrial processes. Its products include desktops and handhelds. The company was founded by Kevin J. Knopp, Miller Scott, Steve Araiza, Andrew Bartfay, Michael Jobin, Christopher D. Brown, and Christopher J. Petty in 2012 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

908 Devices reports revenue growth, eyes biopharma sector improvement

908 Devices showed solid financial performance in 2022, with revenue growth and strategic expansions.
While facing challenges like macro headwinds and lower REBEL placements, the company is focused on innovation.
Opportunities lie in biopharma sector improvement, product utilization rates, and unit growth expectations.
Maintaining a strong cash position and disciplined capital deployment are key strengths for future growth.

908 Devices reports revenue growth and strategic partnerships driving innovation

908 Devices delivered solid performance in Q1 2023, marked by revenue growth, strong recurring revenue, and strategic partnerships driving innovation and market expansion.
While facing challenges in operating expenses and gross margins, the company's focus on handheld devices, recurring revenues, and cost management positions it for future success.
With a robust cash position, ongoing product launches, and a diverse sales funnel, 908 Devices is poised to capitalize on opportunities in the biopharma and cell therapy markets.

908 Devices reports revenue growth and strategic focus for growth

908 Devices showcased revenue growth and strong performance in key product segments. While managing expenses prudently and focusing on key markets, the company faces challenges with a net loss and the need for additional handheld unit growth. Opportunities lie in upcoming product launches, government contracts, and pipeline updates.

908 Devices reports Q3 revenue growth, eyes strong 2024 prospects

908 Devices showed solid performance in Q3 2023, driven by growth in handheld devices and strategic collaborations. Despite challenges in the bio-processing space, the company remains optimistic about future growth and product development.
With a strong cash position, no debt, and a focus on returning to high growth rates, 908 Devices is poised for success in 2024. The company's emphasis on process analytical technology tools and expanding market offerings presents promising opportunities for the future.
While facing challenges in revenue expectations and utilization rates, 908 Devices is actively addressing these issues to drive sustainable growth. The company's commitment to innovation and market expansion positions them well for long-term success.

908 Devices reports strong Q4 performance and optimistic outlook for 2024

908 Devices showed revenue growth and improved net loss in Q4 2023, with a positive outlook for 2024.
The company's strong cash position, successful partnerships, and product confidence are key strengths.
Challenges include margin pressures from pricing adjustments and increased spending.
Opportunities lie in revenue growth guidance, customer interest in new products, and market expansion plans.

908 Devices reports solid Q1 performance, eyes growth opportunities

908 Devices had a strong start in Q1 2024, driven by revenue growth and RedWave acquisition.
Challenges include net loss, declining desktop product revenue, and cost management.
Opportunities lie in engagement with cell therapy accounts, revenue synergies, and cash flow improvement.
Strategic fit of RedWave acquisition offers growth potential and cost synergies in the long term.

908 Devices reports solid Q2 earnings, eyes growth through diversification

908 Devices demonstrated strong revenue growth in Q2 2024, driven by robust performance in handheld forensics devices.
While facing challenges in desktop product revenue, the company's focus on recurring revenue and market expansion bodes well for future prospects.
Strategic adjustments and continued emphasis on operational excellence position 908 Devices for sustained success in diverse markets.

908 Devices faces revenue challenges but pursues growth opportunities

908 Devices reported mixed financial performance in Q3 2024, with revenue growth but falling short of expectations, leading to a net loss.
The company is taking steps to optimize operations, identify growth drivers, and drive margin expansion for future success.
Challenges include revenue guidance adjustments, competitive pressures, and financial losses, which require strategic responses.
Opportunities lie in product innovation, strategic partnerships, and effective implementation of sales strategies to drive growth and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced preliminary, unaudited revenue for the fourth quarter and full year ended December 31, 2021. Preliminary unaudited revenue for the fourth quarter of 2021 is expected to be at least $15.1 million, compared to $5.7 million in the fourth quarter of 2020, reflecting growth of at least 165%. Preliminary unaudited revenue f

908 Devices Announces Preliminary Revenue for the Fourth Quarter and Full Year 2021

GlaxoSmithKline

BOSTON--(BUSINESS WIRE)--908 Devices (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biomolecular analysis, today announced that GlaxoSmithKline (NYSE: GSK) has purchased an additional REBEL™ cell culture media analyzer. GSK will now have a total of five REBEL analyzers being used by its biologics and vaccine process development teams. “We are pleased that GSK has once again chosen our REBEL desktop device as part of its process development efforts to br

908 Devices Announces GSK Purchases Fifth REBEL Cell Culture Media Analyzer

BOSTON--(BUSINESS WIRE)--908 Devices (NASDAQ: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biomolecular analysis, and the United States Forest Service (USFS), an agency of the United States Department of Agriculture (USDA), are collaborating on a research effort to extend the capabilities of the MX908 handheld device for rapid detection of toxic pesticides used in illegal marijuana grows on federal lands. Drug traffickers plant marijuana in remote areas on U.S

908 Devices and U.S. Forest Service Announce Development Collaboration

BOSTON--(BUSINESS WIRE)--908 Devices (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it is teaming with Guardian Centers of Georgia, a world-renowned training facility that specializes in Chemical, Biological, Radiological, Nuclear, and Explosives (CBRNE) programs. Trusted by thousands of first responders, Guardian Centers of Georgia educates clientele with classroom-based courses and realistic practicum ex

908 Devices Teams With World-Renowned Guardian Centers of Georgia for First Responder Training

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (NASDAQ: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the pricing of a public offering of shares of its common stock, with 3,150,000 shares being offered by the Company at a public offering price of $32.00 per share. In addition, 908 Devices has granted the underwriters a 30-day option to purchase up to an additional 472,500 shares of common stock from the Company. The g

908 Devices Announces Pricing of Public Offering

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (NASDAQ: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the launch of a public offering of shares of its common stock, with 2,750,000 shares being offered by the Company pursuant to a registration statement on Form S-1 filed with the Securities and Exchange Commission (the “SEC”). The underwriters will have a 30-day option to purchase up to an additional 412,500 shares of

908 Devices Announces Launch of Public Offering

908 Devices Inc. (MASS) CEO Kevin Knopp on Q3 2021 Results - Earnings Call Transcript

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today reported financial results for the quarter ended September 30, 2021. “We delivered solid results this quarter as we continued to expand our installed base, deepen our relationships and broaden the capabilities of our platforms to deliver even more value,” said Kevin J. Knopp, CEO and Co-founder. “In September, we hosted our fir

908 Devices Reports Third Quarter 2021 Financial Results

PHILADELPHIA--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, announced at the American Society for Mass Spectrometry (ASMS) conference today a new Oligos assay kit for its ZipChip device that enables fast and accurate identification and quantitation of oligonucleotides. Using this new Oligos kit with the ZipChip device, biopharmaceutical lab personnel now have an easy method for high-res

908 Devices Launches Oligos Kit for its ZipChip CE-MS Device

BOSTON--(BUSINESS WIRE)--At the American Society of Mass Spectrometry (ASMS) conference October 31 to November 4 in Philadelphia, 908 Devices Inc. (Nasdaq: MASS) is presenting several talks and posters on the use of high-pressure mass spectrometry and microfluidics separation technologies to accelerate drug discovery workflows, including in metabolomics and proteomics applications. The company, a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analy

908 Devices to Exhibit at ASMS and Present Key Developments in Accelerating Proteomics Workflows

BOSTON--(BUSINESS WIRE)--908 Devices Inc., (Nasdaq: MASS) a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it will report financial results for the third quarter 2021 before market open on Thursday, November 4, 2021. Company management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the compa

908 Devices to Report Third Quarter Financial Results on November 4, 2021

Invitae

Signify Health

ARK Invest's founder and CEO isn't shy about averaging down on her favorite growth stocks.

3 Sinking Stocks Cathie Wood Keeps Buying Anyway

Dynamics Special Purpose Corp

Fate Therapeutics

Khosla Ventures Acquisition Co II

Quantum-Si

Soaring Eagle Acquisition Corp - Unit

Vuzix

Catherine Wood (Trades, Portfolio) disclosed last week her firm, ARK Investment Management, made a number of changes to its portfolio in August.

Cathie Wood Makes Adjustments to Portfolio in August

908 Devices Inc. (MASS) CEO Kevin Knopp on Q2 2021 Results - Earnings Call Transcript

908 Devices Inc (NASDAQ: MASS) reported a second-quarter FY21 revenue decline of 26% year-on-year to $8.3 million, beating the analyst consensus of $7.2 million. The revenue grew 49% Q/Q.

908 Devices Shares Gain On Handheld, Desktop Devices Led Q2 Revenue Beat, FY21 Guidance Above Consensus

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today reported financial results for the quarter ended June 30, 2021. “I am incredibly proud of our team's progress this quarter as we continue to execute on our growth strategy. We have made important strides across our business and are looking forward to continuing this momentum into the second half of the year,” said Kevin J. Knop

908 Devices Reports Second Quarter 2021 Financial Results and Raises 2021 Revenue Outlook

BOSTON--(BUSINESS WIRE)--908 Devices (NASDAQ: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the forthcoming appointment of six new individuals to its Scientific Advisory Board (SAB), including Prof. Ileana Cristea, Prof. Jennifer E. Van Eyk, Prof. Anne-Claude Gingras, Prof. Jesper Olsen, Prof. Renã Robinson, and Prof. John Yates. The new SAB members join the board's co-chairs, Christopher D. Brown, CTO 908 Device

908 Devices Expands Scientific Advisory Board, Creates Dedicated Proteomics Panel

BOSTON--(BUSINESS WIRE)--908 Devices (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the expansion of its channel distribution network, adding new international traction and momentum. 908 Devices handheld and desktop devices are now available across six continents in more than 40 countries and configured in any of six languages. “One of our 2021 goals is to drive expansion across our sales channels, custome

908 Devices Expands Strategic Distribution Network in APAC, Europe, and the Americas

BOSTON--(BUSINESS WIRE)--908 Devices (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced outcomes of its joint innovation partnership with Transcenta, a global biotherapeutics company. Transcenta has implemented 908 Devices' technologies within its Process and Product Development Center and Manufacturing Facility in Hangzhou, China to facilitate their biopharma analytical workflows across large molecule charact

908 Devices and Transcenta's Joint Innovation Partnership Accelerates Biopharma Development

BOSTON--(BUSINESS WIRE)--908 Devices (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced two data analysis partnerships to integrate with the REBEL™, the first at-line fresh and spent cell media analyzer for bioprocess labs. With the integration of leading data exploratory tool Sartorius' SIMCA® and Securecell's Lucullus Process Information Management System (PIMS), users can seamlessly turn REBEL data into dee

908 Devices Announces New Data Integrations with Key Industry Partners to Accelerate BioProcess Data Insights

BOSTON--(BUSINESS WIRE)--908 Devices (NASDAQ: MASS), a pioneer of purpose-built, handheld and desktop mass spectrometry devices for chemical and biomolecular analysis, has appointed Marcia Eisenberg, Ph.D., chief scientific officer of Labcorp Diagnostics, to serve on its Board of Directors effective immediately. Dr. Eisenberg has extensive experience with forensic DNA testing, biotechnology, molecular genetics and molecular oncology. She has helped lead the development and validation of well ov

908 Devices Appoints Marcia Eisenberg, Ph.D., Chief Scientific Officer of Labcorp Diagnostics, to its Board of Directors

908 Devices continues to have real potential, but still has to deliver as the business is quite lumpy. I like the potential of the business, driven by customer testimonials and the addressable market, yet some real execution would be welcomed.

908 Devices: Buying The Dip

908 Devices Inc. (MASS) CEO Kevin Knopp on Q1 2021 Results - Earnings Call Transcript

Q1 2021 Product and Service Revenue Increased More Than 100% Over Prior Year Q1 2021 Product and Service Revenue Increased More Than 100% Over Prior Year

908 Devices Reports First Quarter 2021 Financial Results and Reiterates 2021 Revenue Outlook

BOSTON--(BUSINESS WIRE)--New Features Enable Detection of Aerosols and New Synthetic Drug Targets; Remote Bluetooth App Enables Rapid Data Sharing

News for 908 Devices Stock (MASS)